Antioxidants for the treatment of mild cognitive impairment

Neurological Research

Volumn 26, Issue 5, 2004, Pages 598-602

  Mecocci, Patrizia ^a   Mariani, E ^a   Cornacchiola, V ^a   Polidori, M C ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Dementia; Mild cognitive impairment; Oxidative stress; Therapy

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; COBALAMIN; DONEPEZIL; FOLIC ACID; GINKGO BILOBA EXTRACT; IDEBENONE; SELEGILINE; TACRINE; THIAMINE; THIOCTIC ACID;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DIET SUPPLEMENTATION; DISEASE COURSE; DRUG MEGADOSE; HIGH RISK POPULATION; HUMAN; META ANALYSIS; NEUROIMAGING; NEUROPROTECTION; NEUROPSYCHOLOGICAL TEST; OXIDATIVE STRESS; PATHOGENESIS; SYSTEMATIC REVIEW;

ALZHEIMER DISEASE; ANTIOXIDANTS; BRAIN; CAUSALITY; CLINICAL TRIALS; COGNITION DISORDERS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; OXIDATIVE STRESS; TREATMENT OUTCOME;

EID: 3042798470     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164104225017659     Document Type: Article

References (69)

1. Zabar Y, Kawas CH. Epidemiology and clinical genetics of Alzheimer's disease. In: Clark CM, Trojanowski JQ, eds. Neurodegenerative dementias: clinical features and pathological mechanisms. New York: McGraw-Hill, 2000: pp. 79-94
2. Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive impairment with and without dementia in elderly population. Lancet 1997; 349: 1793-1796
3. Goldman WP, Morris JC. Evidence that age-associated memory impairment is not a normal variant of aging. Alzheimer Dis Assoc Disord 2001; 15: 72-79
4. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999; 56: 303-308
5. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-1992
6. Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: A population-based validation study. Neurology 2001; 56: 37-42
7. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001; 58: 397-405
8. Ganguli M, Dodge HH, Chen P, et al. Ten-year incidence of dementia in a rural elderly US community population: The MoVIES Project. Neurology 2000; 54: 1109-1116
9. Andersen K, Nielsen H, Lolk A, et al. Incidence of very mild to severe dementia and Alzheimer's disease in Denmark: The Odense Study. Neurology 1999; 52: 85-90
10. Paykel ES, Brayne C, Huppert FA, et al. Incidence of dementia in a population older than 75 years in the United Kingdom. Arch Gen Psychiatry 1994; 51: 325-332
11. Sies H. Oxidative stress: Introductory remarks. In: Sies H, ed. Oxidative stress. Orlando: Academic Press, 1985: pp. 1-15
12. De La Torre JC. Impaired brain microcirculation may trigger Alzheimer's disease. Neurosci Biobehav Rev 1994; 18: 397-401
13. De La Torre JC. Vascular basis of Alzheimer's pathogenesis. Ann N Y Acad Sci 2002; 977: 196-215
14. Behl C, Moosmann B. Oxidative nerve cell death in Alzheimer's disease and stroke: Antioxidants as neuroprotective compounds. Biol Chem 2002; 383: 521-536
15. Aliev G, Seyidova D, Lamb BT, et al. Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice. Neurol Res 2003; 25: 665-674
16. Vagnucci AH Jr, Li WW. Alzheimer's disease and angiogenesis. Lancet 2003; 361: 605-608
17. Polidori MC. Oxidative stress and risk factors of Alzheimer's disease: Clues to prevention and therapy. J Alzh Dis 2004; 6: 185-191
18. Perlmutter L, Chui H. Microangiopathy, the vascular basement membrane and Alzheimer's disease: A review. Brain Res Bull 1990; 24: 677-686
19. Beckman KB, Ames BN. The free radical theory of aging matures. Physiol Rev 1998; 78: 547-581
20. Floyd RA, Hensley K. Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol Aging 2002; 23: 795-807
21. Kumar D, Lou H, Singal PK. Oxidative stress and apoptosis in heart dysfunction. Herz 2002; 12: 662-668
22. West IC. Radicals and oxidative stress in diabetes. Diabet Med 2000; 17: 171-180
23. Lewen A, Matz P, Chan PH. Free radical pathways in CNS injury. J Neurotrauma 2000; 17: 871-890
24. Burke A, Fitzgerald GA. Oxidative stress and smoking-induced vascular injury. Prog Cardiovasc Dis 2003; 46: 79-90
25. Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: Potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 2002; 32: 1050-1060
26. Sies H, Stahl W, Polidori MC. Oxidative stress: Antioxidants in degenerative neurological and ophthalmological disorders. In: Bachmann C, Koletzko B, eds. Genetic Expression and Nutrition. Nestlé Nutrition Workshop Series, Pediatric Program, Vol. 50. Philadelphia: Nestec Ltd, Vevey/Lippincott Williams & Wilkins, 2003: pp. 107-118
27. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994; 36: 747-751
28. Mecocci P, Polidori MC, Ingegni T, et al. Oxidative damage to DNA in lymphocytes from AD patients. Neurology 1998; 51: 1014-1017
29. Polidori MC, Stahl W, Eichler O, et al. Profiles of antioxidants in human plasma. Free Radic Biol Med 2001; 30: 456-462
30. Polidori MC, Mecocci P. Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease. J Alz Dis 2002; 4: 513-518
31. Mecocci P, Polidori MC, Cherubini A, et al. Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch Neurol 2002; 59: 794-798
32. Mecocci P. Oxidative stress in mild cognitive impairment and Alzheimer disease: A continuum. J Alz Dis 2004; 6: 159-163
33. Praticò D. F(2)-isoprostanes: Sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 1999; 147: 1-10
34. Praticò D, Clark CM, Liun F, et al. Increase of brain oxidative stress in mild cognitive impairment: A possible predictor of Alzheimer disease. Arch Neurol 2002; 59: 972-976
35. Reich EE, Markesbery WR, Roberts LJ 2nd, et al. Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Am J Pathol 2001; 158: 293-297
36. Montine TJ, Quinn JF, Milatovic D, et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol 2002; 52: 175-179
37. Yan LJ, Levine RL, Sohal RS. Oxidative damage during aging targets mitochondrial aconitase. Proc Natl Acad Sci USA 1997; 94: 11168-11172
38. Tabrizi SJ, Schapira AH. Secondary abnormalities of mitochondrial DNA associated with neurodegeneration. Biochem Soc Symp 1999; 66: 99-110
39. Park LC, Albers DS, Xu H, et al. Mitochondrial impairment in the cerebellum of the patients with progressive supranuclear palsy. J Neurosci Res 2001; 66: 1028-1034
40. Bradley JL, Blake JC, Chamberlain S, et al. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum Mol Genet 2000; 9: 275-282
41. Vasquez-Vivar J, Kalyanaraman B, Kennedy MC. Mitochondrial aconitase is a source of hydroxyl radical. An electron spin resonance investigation. J Biol Chem 2000; 275: 14064-14069
42. Rinaldi P, Polidori MC, Metastasio A, et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 2003; 24: 915-919
43. Behl C, Davis J, Cole GM, etal. Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem Biophys Res Commun 1992; 186: 944-950
44. Harris ME, Hensley K, Butterfield DA, et al. Direct evidence of oxidative injury produced by the Alzheimer's beta-amyloid peptide (1-40) in cultured hippocampal neurons. Exp Neurol 1995; 131: 193-202
45. Behl C. Vitamin E and other antioxidants in neuroprotection. Int J Vitam Nutr Res 1999; 69: 213-219
46. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002; 287: 3223-3229
47. Zandi PP, Anthony JC, Khachaturian AS, and the Cache County Study Group. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study. Arch Neurol 2004; 61: 82-88
48. Morris MC, Beckett LA, Scherr PA, et al. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 1998; 12: 121-126
49. Masaki KH, Losonczy KG, Izmirlian G, et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000; 54: 1265-1272
50. Morris MC, Evans DA, Bienias JL, etal. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002; 287: 3230-3237
51. Morris MC, Evans DA, Bienias JL, et al. Vitamin E and cognitive decline in older persons. Arch Neurol 2002; 59: 1125-1132
52. Commenges D, Scotet V, Renaud S, et al. Intake of flavonoids and risk of dementia. Eur J Epidemiol 2000; 16: 357-363
53. Luchsinger JA, Tang MX, Shea S, et al. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003; 60: 203-208
54. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336: 1216-1222
55. Klatte ET, Scharre DW, Nagaraja HN, et al. Combination therapy of donepezil and vitamin E in Alzheimer disease. Alzheimer Dis Assoc Disord 2003; 17: 113-116
56. Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: Update on a 2-year double-blind multicentre study. J Neural Transm Suppl 1998; 54: 301-310
57. 7Gutzmann H, Kuhl KP, Hadler D, et al. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: Results of a randomized, double-blind, parallel-group multicenter study. Pharmacopsychiatry 2002; 35: 12-18
58. Solomon PR, Adams F, Silver A, et al. Ginkgo for memory enhancement: A randomized controlled trial. JAMA 2002; 288: 835-840
59. Le Bars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997; 278: 1327-1332
60. van Dongen MC, van Rossum E, Kessels AG, et al. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: New results of a randomized clinical trial. J Am Geriatr Soc 2000; 48: 1183-1194
61. Le Bars PL, Velasco FM, Ferguson JM, et al. Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba extract EGb 761 in Alzheimer's disease. Neuropsychobiology 2002; 45: 19-26
62. Hager K, Marahrens A, Kenklies M, et al. Alpha-lipoic acid as a new treatment option for Azheimer type dementia. Arch Gerontol Geriatr 2001; 32: 275-282
63. Nilsson K, Gustafson L, Hultberg B. Improvement of cognitive functions after cobalamin/folate supplementation in elderly patients with dementia and elevated plasma homocysteine. Int J Geriatr Psychiatry 2001; 16: 609-614
64. Blass JP, Gleason P, Brush D, et al. Thiamine and Alzheimer's disease. A pilot study. Arch Neurol 1988; 45: 833-835
65. Nolan KA, Black RS, Sheu KF, et al. A trial of thiamine in Alzheimer's disease. Arch Neurol 1991; 48: 81-83
66. Meador K, Loring D, Nichols M, etal. Preliminary findings of high-dose thiamine in dementia of Alzheimer's type. J Geriatr Psychiatry Neurol 1993; 6: 222-229
67. Sung S, Yao Y, Uryu K, et al. Early Vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J 2003 2004; 18: 323-325
68. Youdim KA, Joseph JA. A possible emerging role of phytochemicals in improving age-related neurological dysfunctions: A multiplicity of effects. Free Radic Biol Med 2001; 30: 583-594
69. Liu RH. Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicals. Am J Clin Nutr 2003; 78 (Supple.): 517S-520S